Business Context and Reporting Period
This Form 8-K Current Report was filed by Senti Biosciences, Inc. on February 6, 2024. The filing addresses a material change in the listing status of the Company's common stock on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Listing Transfer: Effective January 25, 2024, the Company's common stock was transferred from The Nasdaq Global Market to The Nasdaq Capital Market.
- Compliance Extension: On February 6, 2024, Nasdaq granted the Company a second 180-calendar day compliance period (the "Second Compliance Period") to regain compliance with the minimum bid price requirement.
- Deadline: The Second Compliance Period extends until August 5, 2024.
- Requirement: To regain compliance, the Company must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
Outlook, Risks, and Management Commentary
Management intends to closely monitor the closing bid price and has notified Nasdaq of its intention to cure the deficiency by effecting a reverse stock split if necessary. The Company provided no assurance that it will regain compliance during the Second Compliance Period. If the Company fails to demonstrate compliance by August 5, 2024, its stock will be delisted, at which point the Company may appeal the determination to the Nasdaq Hearings Panel.
The filing includes standard forward-looking statement disclaimers regarding clinical trial outcomes, regulatory approvals, and intellectual property risks.
Investor Verification Checklist
- Verify the current trading symbol (SNTI) and exchange tier (Nasdaq Capital Market).
- Monitor the daily closing bid price to track progress toward the $1.00 threshold for 10 consecutive days.
- Watch for announcements regarding a potential reverse stock split to address the bid price deficiency.
- Note the final deadline for compliance is August 5, 2024, after which delisting proceedings may commence.